Black Titan (NASDAQ:BTTC) Shares Down 1% – What’s Next?

Black Titan Corp (NASDAQ:BTTC) shares were down 1% during mid-day trading on Friday . The company traded as low as $1.8007 and last traded at $1.89. Approximately 76,354 shares traded hands during trading, a decline of 98% from the average daily volume of 3,903,502 shares. The stock had previously closed at $1.91.

Wall Street Analyst Weigh In

Separately, Weiss Ratings began coverage on shares of Black Titan in a research report on Monday. They set a “sell (e-)” rating for the company. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, Black Titan has an average rating of “Sell”.

Black Titan Stock Down 1.0%

The firm has a market capitalization of $17.18 million, a PE ratio of -0.64 and a beta of 1.37.

Black Titan Company Profile

Titan Pharmaceuticals, Inc is a biopharmaceutical company developingproprietary therapeutics for the treatment of central nervous system disorders, cancer, and other serious and life threatening diseases. In the central nervous system arena, the company is developing iloperidone, which is clinical testing for schizophrenia through a licensing and development agreement with Novartis Pharma AG. Novartis has tradenamed the product Zomaril.